secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYNAVAX TECHNOLOGIES CORP (—)
CIK:        0001029142
Form:       8-K
Filed at:   2026-02-10T23:59:59+00:00
Accession:  0001193125-26-043821
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.01, 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sanofi completes acquisition of Dynavax for $15.50 per share; shares delisted
-----------------------------------------------------------------------------

- Tender offer accepted 84,680,752 shares (73.92% of outstanding); merger closed under Section 251(h) DGCL.
- Each outstanding share cancelled and converted to $15.50 cash; Dynavax now indirect wholly owned by Sanofi.
- Convertible notes (2.50% 2026 notes $40.2M, 2.00% 2030 notes $225M) amended to convert into cash based on $15.50.
- Board replaced: all prior directors resigned; new directors appointed (T. Grenier, C. Proctor) / officers include R. Spencer as CEO.
- Executives Spencer, Slebir, MacDonald get capped make-whole payments ($5.9M, $2.08M, $1.995M respectively) under letter agreements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1029142/000119312526043821/0001193125-26-043821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1029142/000119312526043821/d945003d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-043821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer